• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon

The OrganoPlate®: A COVID-19 Research Tool

On-Demand Webinar

In light of the current global pandemic, we are in need of research tools that help us to better understand, treat, and prevent COVID-19. In vitro cell culturing systems like the OrganoPlate® allow the development of organ models that recapitulate the complexities of the in vivo organ. These in vitro models are key to understanding the impact of COVID-19 on organ systems.

In this webinar, dr. Kristin Bircsak (MIMETAS) will review how the OrganoPlate® can be a valuable tool for COVID-19 research.

In this webinar, you will learn:

  • How the OrganoPlate® can be used to model target organs of COVID-19, including the kidney, gut, lung and vasculature
  • Which assays can be used to assess the functional and physiological properties of these models, such as barrier integrity and monocyte adhesion.

Register Here


Dr. Kristin Bircsak, Principal Scientist at MIMETAS.
Kristin received her Ph.D. in Toxicology in 2016 from Rutgers University following which she completed a postdoctoral fellowship at the University of Pennsylvania. In her training, Kristin utilized various model system to characterize the negative impact of drugs and environmental chemicals on reproduction and development. In her role at MIMETAS, Kristin drives the development of innovative 3D in vitro organotypic models and assays. Her research is centered on recapitulating the liver and prostate tumor microenvironment to aid in the accurate prediction of safe and effective candidate compounds.

Related publications


May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all